Mangoceuticals’ former subsidiary receives $1.75 million tranche for 17.5% stake
MGRX•MangoRx IP Holdings secured a $1.75 million investment tranche for a 17.5% post-acquisition stake, as part of a $2.5 million investment by two strategic investors. The investment does not issue Mangoceuticals common stock.
1. Investment details
MangoRx IP Holdings, formerly a wholly owned subsidiary of Mangoceuticals, closed an initial $1.75 million tranche for a 17.5% post-acquisition membership interest. A second $750,000 tranche for the remaining 7.5% is due within 60 days or by November 28, 2026; proceeds are intended to support commercialization of the MGX-0024 antiviral patent portfolio.
